VRTX analyst estimates
Vertex (VRTX) analyst ratings, the average price target and its range, and every firm's latest call.
VRTX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital | $576.00 |
| Sep 28, 2026 | UBS | Vertex Pharmaceuticals price target raised to $615 from $585 at UBS | $615.00 |
| Sep 23, 2026 | Jefferies | Vertex (VRTX) PT Raised to $640 at Jefferies | $640.00 |
| Sep 22, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX) | $641.00 |
| Sep 1, 2026 | Goldman Sachs | Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs | $653.00 |
| Sep 1, 2026 | Morgan Stanley | Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley | $665.00 |
| Aug 11, 2026 | Bernstein | Bernstein SocGen Reiterates Outperform Rating on Vertex (VRTX) | $608.00 |
| Aug 10, 2026 | Wolfe Research | Vertex (VRTX) PT Raised to $562 at Wolfe Research | $562.00 |
| Aug 5, 2026 | Barclays | Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays | $617.00 |
| Aug 5, 2026 | Truist Financial | Vertex Pharmaceuticals price target raised to $565 from $560 at Truist | $565.00 |
| Aug 4, 2026 | Stifel Nicolaus | Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel | $500.00 |
| Aug 4, 2026 | Canaccord Genuity | Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord | $442.00 |
| Aug 4, 2026 | Cantor Fitzgerald | Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald | $595.00 |
| Jul 13, 2026 | Truist Financial | Vertex Pharmaceuticals price target raised to $560 from $542 at Truist | $560.00 |
| Jul 13, 2026 | UBS | Vertex Pharmaceuticals price target raised to $585 from $545 at UBS | $585.00 |
- 23 firms rate VRTX: 19 buy, 3 hold, 1 sell.
- The average price target is $590.69 from 13 analysts, from $442.00 to $665.00.
Updated 2026-11-02 17:51 UTC